Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 51 to 60 of 2003

TitleReference numberPublishedLast updated
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTA1090
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1088
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)TA1089
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollenTA1087
Single-step scaffold insertion for repairing symptomatic chondral knee defectsIPG793
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTA1085
Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessmentHTE30
Cenobamate for treating focal onset seizures in epilepsyTA753

Results per page

  1. 10
  2. 25
  3. 50
  4. All